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Rationale Functional strength training in addition to conven-
tional physical therapy could enhance upper limb recovery
early after stroke more than movement performance therapy
plus conventional physical therapy.
Aims To determine (a) the relative clinical efficacy of conven-
tional physical therapy combined with functional strength
training and conventional physical therapy combined with
movement performance therapy for upper limb recovery;
(b) the neural correlates of response to conventional physical
therapy combined with functional strength training and con-
ventional physical therapy combined with movement perfor-
mance therapy; (c) whether any one or combination of
baseline measures predict motor improvement in response to
conventional physical therapy combined with functional
strength training or conventional physical therapy combined
with movement performance therapy.
Design Randomized, controlled, observer-blind trial.
Study The sample will consist of 288 participants with upper
limb paresis resulting from a stroke that occurred within the
previous 60 days. All will be allocated to conventional physical
therapy combined with functional strength training or conven-
tional physical therapy combined with movement perfor-
mance therapy. Functional strength training and movement
performance therapy will be undertaken for up to 1·5 h/day,
five-days/week for six-weeks.
Outcomes and Analysis Measurements will be undertaken
before randomization, six-weeks thereafter, and six-months
after stroke. Primary efficacy outcome will be the Action
Research Arm Test. Explanatory measurements will include
voxel-wise estimates of brain activity during hand movement,
brain white matter integrity (fractional anisotropy), and brain–
muscle connectivity (e.g. latency of motor evoked potentials).
The primary clinical efficacy analysis will compare treatment
groups using a multilevel normal linear model adjusting for
stratification variables and for which therapist administered
the treatment. Effect of conventional physical therapy com-
bined with functional strength training versus conventional
physical therapy combined with movement performance
therapy will be summarized using the adjusted mean differ-
ence and 95% confidence interval. To identify the neural cor-
relates of improvement in both groups, we will investigate
associations between change from baseline in clinical out-
comes and each explanatory measure. To identify baseline
measurements that independently predict motor improve-
ment, we will develop a multiple regression model.
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Introduction
This trial addresses an important focus for stroke rehabilitation:
the ability of stroke survivors to recover the use of their arm and
hand for everyday functional tasks such as picking up a cup,
unscrewing a coffee jar lid, and doing up buttons and zippers.
Limitations in performing such everyday tasks seriously affect
capacity for independent living. At six-months after stroke, only
38% of people who receive rehabilitation have recovered some
dexterity (1).
Systematic reviews [for example (2)] indicate that repetitive
functional task-specific activity can enhance motor recovery. Two
training modalities that have attracted considerable attention are
constraint-induced movement therapy (CIMT), which consists of
repetitive practice of functional tasks combined with constraint of
the ipsilesional upper limb, and robot-assisted therapy (RAT),
which provides repetitive practice of movements that are required
for upper limb functional activity. CIMT is effective between
three- and nine-months after stroke (3) but less so when given
early after stroke (4). Furthermore, CIMT is suitable only where at
least 10 degrees of active movement are present in the paretic
thumb and two or more paretic fingers (5). This requirement for
a high level of function excludes many stroke survivors (6). RAT
has been used in a wider group of stroke survivors but has also
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been found to be no more effective than an equal dose of conven-
tional therapy (7). Thus, the question of whether a novel treat-
ment aimed at enhancing upper limb functional task-specific
activity might be better than routine conventional physical
therapy (CPT) remains unanswered.
Functional strength training (FST) combines functional task-
specific exercise and strength training, the latter of which is
included because the largest impact on upper limb functional
recovery after stroke may result from loss of muscle strength (8).
Importantly, preliminary data indicate FST may be more effective
than another therapy, movement performance therapy (MPT), at
equal intensity (9). Both FST and MPT are used in routine CPT.
Evaluation of FST through properly designed clinical trials is
crucial.We are aware, however, that a potentially serious barrier to
the development of any novel treatment for poststroke motor
impairment arises from poor understanding of its mechanisms of
action and, in particular, whether it is likely to work in all stroke
sub-groups (10). The CIMT and RAT trials recruited patients
based on clinical phenotype, but in order to target therapy to those
most likely to benefit, this may not be sufficient. It is increasingly
recognized that large rehabilitation trials need to include more
sophisticated measures of residual brain structure and function in
order for researchers to understand the mechanisms of action of
treatment and the characteristics of ‘responsive’ patients (10,11).
For example, both the pretreatment level of brain activity in
primary motor cortex during the performance of a motor task
(12) and the degree of damage to descending motor white matter
pathways (13) were associated with greater clinical improvement
in 24 chronic stroke patients undergoing two-weeks of robot-
based therapy. These studies are encouraging, but if we are to
incorporate such data into models that can accurately predict
therapeutic response, larger sample sizes are clearly required.
Specific objectives of this trial are the following:
1. to determine whether CPT + FST commenced early after
stroke produces greater improvements in upper limb motor
recovery than CPT + MPT;
2. to identify similarities and differences in the neural correlates
of clinical improvement in response to (a) CPT + FST and
(b) CPT + MPT;
3. to determine whether any pretreatment parameters or combi-
nations are sufficiently predictive of improvement in upper limb
motor function in response to intervention to enable physical
therapy to be targeted at those most likely to respond;
4. to provide estimates of the preliminary cost-effectiveness of
CPT + FST and inform the design of a subsequent pragmatic trial.
Methods
Design
The trial will be a randomized, controlled, observer-blind trial
(Fig. 1).
Study population
Study criteria (combined inclusion and exclusion) are as follows:
Ë aged 18 + years;
Screening and recruitment
Informed consent
Baseline measures – blinded
(day 1)
Randomization
Conventional physical therapy
+
functional strength training 
up to 1.5 h a day, five-days a week for six-weeks
(day 2 to 42)
Conventional pysical therapy
+
movement performance therapy
up to 1.5 h a day, five-days a week for six-weeks
(day 2 to 42)
Outcome measures – blinded
(day 43 ± 7 days)
Follow-up measures – blinded
(6 months after stroke ± 14 days)
Fig. 1 Flow diagram to illustrate trial design.
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Ë infarction in anterior cerebral circulation territory within the
previous 60 days, confirmed by clinical neuroimaging;
Ë score at least 11/33 forMotricity Indexpinch section (14) but un-
able to complete the nine-hole peg test (9HPT) (14) in 50 s or less;
Ë no obvious spatial neglect as defined by a score of 0 or 1 on
Extinction and Inattention sub-scale of the NIH Stroke Scale;
Ë no obvious motor dyspraxia or communication deficits as
assessed by ability to imitate action with the nonparetic upper
limb, as in previous pilot work (15);
Ë able, prior to the index stroke, to use the paretic upper limb to
lift a cup and drink from it.
Randomization
The randomization sequence, generated in advance, will stratify
participants by clinical center, time after stroke (up to 30 days and
31–60 days), and ability to use the paretic upper limb as assessed
by the 9HPT (14) (substantial impairment = able to move one
peg or less in 50 s; moderate impairment = able to move two or
more pegs in 50 s). An independent telephone randomization
service will maintain allocation concealment from the research
team prior to randomization. An independent statistician at the
Robertson Centre will generate the randomization sequence and
will not be involved in developing the statistical analysis plan or
programming the trial statistical analysis.
Interventions
The intervention phase will last for six-weeks. All participants will
receive routine CPT provided by the clinical physiotherapists, as
in previous pilot work (9). Training will be provided for them to
record content and amount of therapy provided daily for home
participants, outpatients, and inpatients.
In each clinical center, the extra therapy will be provided by a
research therapist responsible for either extra MPT (control) or
extra FST (experimental). We will not tell clinical staff which
research therapist is responsible for which treatment. This strat-
egy is expected to minimize the potential for therapist bias,
although allocation to different forms of exercise-based therapy is
more difficult to conceal than, for example, an active or placebo
drug, because of observable differences.
Participants in both groups will take part in extra therapy, as
prescribed and overseen by a research therapist through direct
and nondirect contact, for up to 1·5 h a day, five-days a week for
six-weeks. The research therapists will be trained to direct either
FST or MPT in accordance with a standardized manual before the
trial begins. Fidelity to the manuals will be assessed at the begin-
ning and at regular points throughout the trial with little prior
warning to therapists.
Control intervention (CPT + MPT)
MPT is the component of CPT which emphasizes movement
quality rather than quantity. It is based on neurophysiological
approaches for which there is evidence that they produce no effect
compared with no treatment or a placebo (16). MPT involves
joint and soft tissue mobilization, sensory stimulation, facilitation
of muscle activity/movement, positioning, retraining normal pat-
terns of movement, and education for the patient/carer. Emphasis
is given to hands-on interventions provided by a therapist facili-
tating and guiding movement (therapist-dependent) to provide
sensory input and to optimize postural control and joint align-
ment in preparation for voluntary movement. Some repetitive
practice of functional tasks is included, but without systematic
progression in resistance to movement.
Feedback and instructions during MPT encourage an internal
focus of attention on the movement performance, for example,
amount and direction of elbow movement when lifting a teapot.
Experimental intervention (CPT + FST)
FST involves repetitive progressive resistive exercise during goal-
directed functional activity, with the therapist providing verbal
prompting and feedback (therapist-independent). FST is based
on the key elements of normal upper limb function (i.e., posi-
tioning the hand and then using it to manipulate objects) and is
therapist-independent while maintaining participant safety. The
focus is on improving the power of shoulder/elbow muscles to
enable appropriate placing of the hand, improving production of
appropriate force in arm and hand muscles to achieve a specific
grasp, and specific resistive functional practice for wrist and finger
muscles to maximize ability to manipulate objects. The initial
level of load/resistance is the maximum load that still permits five
repetitions of action through the available range of muscle length.
Treatment is progressed systematically using repetition and
increased resistance tomovement by changing the limb’s relation-
ship to gravity, changing the amount of friction to overcome, and
increasing the size and weight of items (e.g., following an empty
cup with a cup containing an increased volume of water). FST
involves specific movements for muscle groups, upper limb gross
movement patterns underlying functional activity, hand
reaching/retrieval activities, hand grip activities, hand manipula-
tion involving entire everyday movements, and using objects such
as screw-top canisters, pegs, mugs, and pens. These movements
are extended into more complex everyday activities such as
placing different food items into a shopping bag, then lifting the
bag onto a shelf; tightening/loosening nuts/bolts; opening a bottle
and drinking from it; and pouring tea from a pot.
Feedback and instructions encourage an external focus of
attention on the effects of movements, for example, whether the
teapot has been lifted clearly off the table.
Outcomes
In accordance with the intention-to-treat principle, every effort
will be made to include all randomized participants at outcome
and follow-up whether or not they discontinue randomized treat-
ment before the end of the intervention phase.Measurements will
be made and processed by assessors blinded to treatment alloca-
tion. To assess whether blinding was achieved, we will ask asses-
sors, at outcome and follow-up points, to guess participants’
group allocation. Agreement with actual allocation will be
assessed with Cohen’s kappa.
Clinical efficacy measures will be made pre-randomization
(baseline), the day (± 7) after the six-week intervention phase
ends (outcome), and six calendar months (± 14 days) after the
index stroke (follow-up).
The primary outcome measure will be the score on the Action
Research Arm Test (ARAT) (17), a measure of the primary focus
of both interventions – improved upper limb function.
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Secondary outcome measures will be (a) Wolf Motor Function
Test (WMFT) score (18), (b) hand grip force, and (c) pinch grip
force. The upper limb positions for both pinch grip force and
hand grip force will be standardized and the myometer set to zero
after the participant’s hand/digits are positioned around the bars,
‘at rest’. The instruction given will be ‘squeeze as hard as you can’.
Force values will be obtained over three trials, with the greatest
value obtained used for data analysis.
Explanatory measures will be made at baseline and outcome.
Full training will be given to all trial center teams, with compre-
hensive monitoring and supervision arrangements. Data from all
sites will be subject to prompt, rigorous quality control prior to
statistical processing. All participants will be provided with full
explanations and opportunities to ask questions, plenty of time to
be made comfortable, and plenty of time to practice the tasks.
Structural brain imaging will be conducted in all patients in the
same location during the same session.
First, a T1-weighted, 1 × 1 × 1-mm whole-brain image will be
obtained using structural magnetic resonance imaging (MRI).
Automated normalization, segmentation, and lesion identifica-
tion will be performed as previously described (19), using
spm12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12). This
approach has a high sensitivity for delineating brain lesions and
identifying tissue classes, thereby being useful in atrophy and
white matter disease. Outputs include normalized lesion maps as
well as gray and white matter maps consisting of voxel-wise values
representing gray or white matter density.
Second, a map of the static magnetic field will be generated to
allow for offline correction of image distortions.
Third, diffusion tensor imaging (DTI) data will be acquired at
2 × 2 × 2 mm. A diffusion tensor model will be fitted to data at
each voxel to allow for maps of diffusion parameters (fractional
anisotropy, mean diffusivity, and eigenvalues) to be generated for
each participant at each scanning session. Probabilistic tractogra-
phy (http://www.fmrib.ox.ac.uk/fsl) will be used to generate path-
ways of interest across the group (19), in particular the
corticospinal tract.
Fourth, dual-echo T2-weighted and proton-density whole-
brain MRI scans will be acquired at 1 × 1 × 3 mm resolution to
allow for accurate delimitation of stroke volumes and for
detection of other pathological changes, such as white matter
hyperintensities.
A key purpose of FST is to improve the production of appro-
priate force in different muscles to enhance grasping andmanipu-
lation of objects by the paretic hand. We will therefore use a grip
force task for functional MRI (fMRI), which is able to detect
changes in brain activity corresponding to a force as low as 0.01N.
As all participants will be able to produce the beginnings of pre-
hension, they will be able to perform the fMRI grip task. Partici-
pants will be scanned while performing isometric handgrips of
between 20% and 50% of paretic hand maximum grip force as
measured just prior to scanning. Participants will be trained in
how to perform the task prior to scanning. The experiment will be
conducted according to an event-related design (auditory cues
given at interstimulus interval of 7 ± 2 seconds) with actual
exerted force recorded (20).
Analysis of fMRI data will follow standard approaches using
spm12. Single-participant results will include voxel-wise values
for (a) magnitude of brain activity during handgrips and (b) how
much brain activity is modulated by handgrip force (20%, 50%).
These values are independent of one another and provide
complementary information on how the brain is working to gen-
erate motor output. In addition, we will use dynamic causal mod-
eling (DCM) (21) to measure (a) connectivity between brain
regions (coupling parameters) during grip and (b) changes in
connectivity between brain regions (bilinear parameters) with
increasing grip force.
Single pulses of transcranial magnetic stimulation (TMS),
using a standard figure-of-eight coil, will be given over the hand
and arm areas of the primary motor cortex of the lesioned hemi-
sphere and, when possible, the nonlesioned hemisphere. Electro-
myographic recordings of motor evoked potentials (MEPs) over
both contralateral and ipsilateral extensor carpi radialis and
biceps brachii muscles will allow for characterization of recruit-
ment curves, which will be constructed by measuring the ampli-
tude of the MEP at between 100% and 130% (where possible) of
active motor threshold (20,22).
Economic evaluation
Costs and effects will be monitored at baseline and outcome in
order to inform the design of a future Phase III study. A prelimi-
nary estimate of cost-effectiveness will also be made. Resource
items to be monitored will include input by the research therapist,
length of stay in the original admission and any subsequent read-
mission, and other health-care and non-health-care contacts.
Levels of informal care will also be monitored. The EuroQoL-5D
(23) will be the main measure of effect, as it can be used to
estimate the quality-adjusted life year gain.
Assessment of safety
Comprehensive details of the trial safety monitoring process
can be found in the operational trial protocol (http://
www.fastindicate.com). In addition to events that may be
expected to occur in a trial of this type, pain and fatigue will be
particularly monitored, as there is a possibility that either MPT or
FST, carried out in addition to CPT, could be associated with
overuse syndrome, expressed by experience of pain or fatigue.
We will follow the Norwich Clinical Trials Unit system of
documenting and reporting serious adverse events (http://
www.nnuh.nhs.uk/Dept.asp?ID=681). Adverse events will be
recorded from randomization to end of trial.
Data monitoring body
Ethical approval has been provided by the National Research
Ethics Service. The University of East Anglia is the trial sponsor.
All necessary local R&D governance approval will be obtained for
each center in advance of recruitment. This trial is registered with
Current Controlled Trials (ISRCTN19090862) and the UK Clini-
cal Research Network Study Portfolio (UKCRN ID 12967). Inde-
pendent trial oversight will be provided by a trial steering
committee and a data monitoring and ethics committee set up in
adherence to the UK Medical Research Council Guidelines for
Good Clinical Practice in Clinical Trials.
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Sample size
The clustered data structure (patients grouped according to
therapist within each treatment group) is accounted for in the
design and analysis (24). This sample size calculation is based on
actual ARAT data from our previous early-phase trial (9). Assum-
ing an intraclass correlation coefficient of 0·01 in both treatment
arms and three centers with a separate therapist for each random-
ized arm, a sample size of 99 participants per group would have
80% power to detect a clinically important mean difference of 6·2
in ARAT change when data were analyzed using a two-sample
t-test with Satterthwaite correction, applying a 5% two-sided sig-
nificance level and allowing for potentially different standard
deviations in the CPT + MPT (7·9) and CPT + FST (19·3) groups.
To account for clustering in the design (participants grouped
according to therapist within each randomized treatment at each
study site), a sample size inflation factor, 1 + (m-1)*ICC, is
applied, where m is the cluster size and ICC is the intraclass
correlation coefficient. Assuming that recruitment is evenly dis-
tributed across therapists, sample size is therefore inflated to 129
evaluable participants per group. The corresponding mean differ-
ences in ARAT change that would be detectable in a study of this
size for ICCs of 0·02 and 0·03 would be 7·0 and 7·8 respectively,
showing that the design is fairly insensitive to assumptions about
the ICC. Finally, to allow for an attrition rate of 10% [7% in our
previous single-center trial (9)], 144 participants per group will
be recruited for a total sample size of 288.
For the explanatory measurements, our experience indicates
that of those meeting the criteria for this proposed trial, at least
70% will consent to participate, and 90% of these will complete
the measurements. Thus, we anticipate 181 sets of explanatory
measurements.
Statistical analysis
Data for all participants will be analyzed according to partici-
pants’ allocated group. A single formal analysis will take place at
the end of the study. Interim data summaries will be made avail-
able to the independent data monitoring and ethics committee.
With regard to missing data, we shall aim to do the following
(25): (1) implement strategies to limit the amount of missing
data; (2) develop an understanding of the causes for data being
missing and (3), based on this, decide what the main assumption
about the mechanism of missing data is; (4) conduct a statistical
analysis which accounts for this assumption; and (5) perform
sensitivity analyses to assess whether the conclusions depend
strongly on the validity of the main assumption about the mecha-
nism of missingness.
Clinical efficacy
Continuous outcome variables will be compared between treat-
ment groups using a multilevel normal linear model. Change
from baseline to outcomes (day 43; Fig. 1) will be modeled,
adjusting for baseline value, time after stroke, and 9HPT score as
patient-level covariates. Which therapist administered the treat-
ment will be included in the model as a zero-mean random effect.
We will test, by comparing the log-likelihood, whether a separate
random-effect variance is required for therapists delivering each
treatment arm or whether a pooled variance is sufficient. The
treatment effect will be summarized using the adjusted mean
difference and 95% confidence interval.
Secondary analyses will include sensitivity to incomplete
follow-up, descriptive analysis at each time-point, statistical mod-
eling of follow-up measures at six-months, and a per-protocol
analysis. For safety analysis, the number and percentage of par-
ticipants experiencing each prespecified category of adverse event
will be summarized by treatment group.
Neural correlates of response to CPT + FST and
CPT + MPT
Our main intention with these analyses is to infer differences
between correlations between neural explanatory measurements
and CPT + FST and those between such measurements and
CPT + MPT (objective 2). Associations will be investigated
between change from baseline in clinical outcomes and change
from baseline in each of the explanatory measurements. We will
make every possible effort to record and adjust for potential con-
founding baseline variables, such as baseline motor score.
The relationship will be explored further via multilevel linear
regression, which will include which therapist administered the
treatment as a random effect., We will assess whether changes in
neuroimaging and/or neurophysiological measures are strongly
associated with clinical improvements in the individual partici-
pant and, in particular, whether such associations differ between
the CPT + FST and CPT + MPT groups. We acknowledge the
potential value of structural mean models (SMM)/causal infer-
ence (CI) and are aware of the additional complexity due to
clustering in the design. Therefore, we will investigate an exten-
sion of SMM/CI as a potential exploratory analysis (26).
The relationship will be explored further via multilevel linear
regression which will include therapist as a random effect.We will
assess whether changes in neuroimaging and/or neurophysiologi-
cal measures are strongly associated with clinical improvements
in the individual participant and in particular whether such asso-
ciations differ between the CPT+FST and CPT+MPT groups.
Indicators of response to CPT + FST and CPT + MPT
Baseline measurements considered will be (a) TMS- and DTI-
based measurements related to corticospinal system integrity,
(b) normalized lesion maps, (c) voxel-wise measurements of gray
and white matter density, (d) voxel-wise measurements of brain
activity during hand grip and its modulation by changing force,
and (e) clinical variables, including motor scores. An interaction
term between treatment group and each variable from (a) to (e)
in turn will be added to the normal linear model for ARAT used
in the clinical efficacy analysis. Continuous baseline variables will
be categorized as high or low, the cutpoint being at the median of
the observed data.We will adjust for the time after stroke category.
Statistical significance of the interaction term will be assessed and
treatment effect calculated within each of the high and low sub-
groups of the interaction variable.
Further analysis will develop a multiple regression model
within each treatment group to predict change in ARAT clinical
outcome using baseline measurements. This will determine the
sub-set of baseline variables independently associated with treat-
ment response and will allow for a different group of baseline
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predictors within each treatment group. Principal components
analysis will be used to reduce dimensionality of the predictor
variables while retaining a meaningful interpretation of the prin-
cipal components.
Trial funding
FAST INdiCATE is funded by the Efficacy and Mechanism Evalu-
ation programme (http://www.eme.ac.uk). EME reference:
10/60/30
Summary
This trial aims to determine clinical efficacy of CPT + FST and
CPT + MPT for enhancement of upper limbmotor function early
after stroke, neuro-biomechanical correlates associated with clini-
cal improvement, and which stroke survivors may be most likely
to respond to FST and which to MPT. The results are expected to
inform a subsequent definitive clinical trial and also to lead to
advances in knowledge of how the upper limb recovers after
stroke in response to well-characterized interventions.
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